Pathogen Identification in Pediatric Hematopoietic Stem Cell Transplant Patients with Suspected Lower Respiratory Tract Infection Save

Date Added
December 6th, 2016
PRO Number
Pro00060294
Researcher
Michelle Hudspeth
Keywords
Adolescents, Children's Health, Immune System, Lung, Pediatrics, Transplant
Summary

This study is for patient that have been diagnosed with suspected lower respiratory tract infection. The purpose of this study is to evaluate a new test that may be able to find more lung infections than current tests can. This new test is called next-generation sequencing and looks in respiratory secretions for bacteria, viruses, fungi, and other organisms that may cause infection. We hope to learn more about the usefulness of this new test in identifying infections.

Institution
MUSC
Recruitment Contact
Thomas Hortman
864-792-9579
hortman@musc.edu

A Multicenter Pilot Study of Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Targeted Immunotherapy in Children, Adolescents and Young Adults with Poor Risk CD30+ Hodgkin Lymphoma (HL) Save

Date Added
June 7th, 2016
PRO Number
Pro00050306
Researcher
Michelle Hudspeth
Keywords
Cancer, Cancer/Lymphoma, Drug Studies
Summary

This study is for subjects who have been diagnosed with a type of lymph gland disease called Hodgkin Lymphoma which has come back or has not gone away after treatment, including the best treatment known for these diseases. Researchers believe subjects will benefit from an allogeneic (from another human) stem cell transplant which has been offered as a form of treatment for this disease in many other patients. After transplant we will provide a type of medication that targets the CD30+ protein, a protein that is commonly expressed in Hodgkin Lymphoma. This medication is called Brentuximab Vedotin (or Brentuximab). Subjects will be offered treatment with lower doses of chemotherapy drugs, as compared to the higher doses of chemotherapy drugs historically used in transplants for other diseases. This is known as reduced intensity therapy.The main purpose of this study is to determine the safety and outcome of following reduced intensity conditioning and allogeneic stem cell transplantation in selected patients with Hodgkin Lymphoma (specifically CD30+ HL patients) with Brentuximab Vedotin. Subjects can expect to be in this study for 3 years.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

A Pediatric Blood and Marrow Transplant Consortium (PBMTC) multi-center Phase II Pilot Trial of Myeloablative Conditioning and Transplantation of Partially HLA-mismatched T cell replete Bone Marrow with post-transplantation cyclophosphamide for Children and Young Adults with Hematologic Malignancies Save

Date Added
May 3rd, 2016
PRO Number
Pro00054276
Researcher
Michelle Hudspeth
Keywords
Cancer, Cancer/Other, Men's Health, Transplant, Women's Health
Summary

This study is for participants who have been diagnosed with cancers of the blood who do not have a related perfect tissue ?match? for BMT. This research is being done to find out if a bone marrow transplant (BMT) from a relative who is not a perfect tissue match is safe and effective in people with cancer. The primary goal of this study is to use chemotherapy and/or radiation therapy to completely get rid of a person?s existing bone marrow, give them new bone marrow from a relative who is not a perfect tissue match, and then give them two doses of additional chemotherapy shortly after receiving the new bone marrow. Participants can expect to be in this study for up to 2 years.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Community Central Line Infection Prevention Trial Save

Date Added
February 28th, 2015
PRO Number
Pro00040608
Researcher
Michelle Hudspeth
Keywords
Pediatrics
Summary

The overall goal of this Community Central Line Infection Prevention (CCLIP) trial is to determine whether use of a promising new intervention, namely 70% isopropyl alcohol embedded protective caps on central lines, in the home setting is associated with a reduction in ambulatory central line-associated bloodstream infections (CLABSI) in a high-risk population of pediatric hematology/oncology patients. This proposed research, working with an anticipated 24 children?s hospitals, will layer a cluster-randomized, cross-over design, clinical trial to standardize and spread best-practice care bundles among caregivers for children with chronic hematologic/oncologic conditions. This proposal will be first prospective trial of a promising new intervention and will focus on the caregivers integral to ambulatory pediatric central line care: patients and families. Successful completion of this project will give healthcare providers, patients, payers, and policymakers generalizable and effective tools for spreading CLABSI eradication efforts outside hospitalized settings.

Institution
MUSC
Recruitment Contact
Michelle Hudspeth
2-2957
hudspeth@musc.edu

Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies Save

Date Added
February 3rd, 2015
PRO Number
Pro00041150
Researcher
Michelle Hudspeth
Keywords
Cancer/Leukemia, Cancer/Lymphoma
Summary

This clinical trial is being done to collect information about various long-term effects commonly seen in children who survive a stem cell transplant. In particular, information about renal (kidney), cardio-metabolic (heart disease and diabetes) and skeletal (bone) long-term effects will be collected for two years after transplant.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Change_preferences

-- OR --

Create_login